Trial reportBMC infectious diseases2025
Immunogenicity and safety of a booster dose of the COVID-19 DNA vaccine in healthy adults aged 18 years and above: a single-center, randomized, observer-blind, placebo-controlled phase 2 trial.
Trial report in BMC infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
backgroundA two-dose primary regimen of INO-4800 DNA vaccine demonstrated only modest immunogenicity in the previous phase 2 clinical trial. This booster study aimed to evaluate the immunogenicity and safety of a booster dose of INO-4800 in adults previously received two-dose regimen of INO-4800.
methodsHealthy adults who received two doses of INO-4800 (1.0 mg or 2.0 mg) at least 12 months ago in a previous phase 2 trial were eligible for this booster study, conducted in Danyang, Jiangsu Province, China. Eligible participants were stratified by primary vaccination dose (1.0 mg or 2.0 mg) and age group (18-59 years or ≥ 60 years), and subsequently randomized in a 1:1 ratio to receive a third dose of INO-4800 or placebo at the same dosage as previously administered. The primary immunogenicity endpoint was the geometric mean concentrations (GMCs) of spike-binding antibodies on day 14 post-booster. The primary safety endpoint was the occurrence of adverse reactions within 14 days.
resultsBetween December 20 and 23, 2021, 200 eligible participants were enrolled. 100 eligible participants who received two doses of 2.0 mg INO-4800 were randomly assigned (1:1) to receive a third dose of 2.0 mg INO-4800 (n = 50) or 2.0 mg placebo (n = 50). Another 100 eligible participants who received two doses of 1.0 mg INO-4800 were randomly assigned (1:1) to receive a third dose of 1.0 mg INO-4800 (n = 50) or 1.0 mg placebo (n = 50). On day 14 post-booster, the GMCs of spike-binding antibodies were significantly higher in 2.0 mg INO-4800 group ( 260.1 BAU/mL) compared to placebo group (2.8 BAU/mL, p < 0.001), and in 1.0 mg INO-4800 group (104.2 BAU/mL) compared to placebo group (2.5 BAU/mL, p < 0.001). The most common local reactions were injection site redness, occurring at rate of 16.0% in the INO-4800 groups.All adverse reactions were mild to moderate in severity and occurred within 14 days post-booster. No vaccine related serious adverse events were reported.
conclusionsThe booster regimen of one dose INO-4800 is safe and modestly immunogenic in individuals who previously received a two- dose regimen of INO-4800, with the 2.0 mg INO-4800 demonstrating superior immunogenicity compared to the 1.0 mg INO-4800.
trial registrationwww.chictr.org.cn , identifier is ChiCTR2100054324.(December 13 2021).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.